This study tested the effects of interfering with F-actin dynamics in HER2+ cancer cells, in combination with existing HER2+ cancer therapies, as an alternative approach to target key properties of metastasis-initiating cells11,16,17,29. The gene discussed is ERBB2; the disease is cancer.